Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati/Barrett Cancer Center
mi
from
Cincinnati, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati/Barrett Cancer Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Columbus NCI Community Oncology Research Program
mi
from
Columbus, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Columbus NCI Community Oncology Research Program
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Genesis Healthcare System Cancer Care Center
mi
from
Zanesville, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Warren Clinic Oncology-Tulsa
mi
from
Tulsa, OK
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Warren Clinic Oncology-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Jefferson Regional Radiation Oncology
mi
from
Pittsburgh, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Jefferson Regional Radiation Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Main Line Health NCORP
mi
from
Wynnewood, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Main Line Health NCORP
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Saint Mary's
mi
from
Green Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
ProHealth D N Greenwald Center
mi
from
Mukwonago, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
ProHealth Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Sturgeon Bay
mi
from
Sturgeon Bay, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
ProHealth Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Mercy Clinic-Rolla-Cancer and Hematology
mi
from
Rolla, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Akron General
mi
from
Akron, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Akron General
mi
from
Akron, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
University Hospitals Portage Medical Center
mi
from
Ravenna, OH
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
University Hospitals Portage Medical Center
mi
from
Ravenna, OH
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
UPMC Jameson
mi
from
New Castle, PA
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
UPMC Jameson
mi
from
New Castle, PA
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Saint Francis Medical Center
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Fort Worth Cancer Center
mi
from
Fort Worth, TX
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Fort Worth Cancer Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas
Status: Enrolling
Updated:  12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas
Status: Enrolling
Updated: 12/31/1969
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas
A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
mi
from
Wauwatosa, WI
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Three-Factor Eating Questionnaire in Measuring Eating Behavior in Adolescent and Young Adult Survivors of CNS Tumors
MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of CNS Tumors
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Three-Factor Eating Questionnaire in Measuring Eating Behavior in Adolescent and Young Adult Survivors of CNS Tumors
MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of CNS Tumors
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Brain Metastasis
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Brain Metastasis
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center-Mission Bay
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated:  12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials